1[1]Jones P,Kafonek S,Laurora I,et al.Comparative dose efficacy study of atorvastatin versus simvastatin,lovstatin,and fluvastatin in patients with hypercholesterolemia (the CURVES study)[J].Am J Cardiol,1998,81:582-587.
2[2]Jones PH,Mckenney JM,Karalis DG,et al.Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia[ J ].Am Heart J,2005,149:e1.
3[3]Andrens TC,Ballantyne CM,Hsia JA,et al.Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins[ J].Am J Med,2001,111:185-191.
4[4]Newman CB,Palmer G,Silbershatz H,et al.Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients[ J].Am J Cardiol,2003,92:670-676.
5[5]Ferrier KE,Muhlmann MH,Baguet JP,et al.Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertensions[ J].J Am Coll Cardiol,2002,39:1020-1025.
6[6]Athyros VG,Mikhailidis DP,Papageorgiou AA,et al.The effect of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease,A subgroup analysis of the Greek atovastatin and coronary heart disease evaluation (GREACE) study[ J ].J Clin Pathol,2004,57:728-734.
7[7]Strandberg TE,Vanhanen H,Tikkanen MJ,et al.Effect of statins on C-reactive protein in patients with coronary heart disease[J].Lancet,1999,353:118-119.
8[8]Schwartz GG,Olsson AG,Ezekowitz MD,et al.Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:the MIRACL study:A randomized controlled trial[J].JAMA,2001,285:1711-1718.
9[9]Nissen SE,Tuzcu EM,Schoenhagen P,et al.Effect of intensive compare with moderate lipid-lowering therapy on progression of coronary atherosclerosis:a randomized controlled trial[ J].JAMA,2004,291:1071-1080.
10[10]Hilgendorff A,Muth H,Parviz B,et al.Statins differ in their ability to block NF-KappaB activation in human blood monocytes[ J ].Int J Clin Pharmacol Ther,2003,41:397-401.
